The peptide Modified GRF 1-29 comprised 29 amino acids and was manufactured in a laboratory. The naturally existing growth hormone-releasing hormone (GHRH) has been structurally altered to offer more stable groups in modified GRF 1-29 peptide (Mod GRF 1-29), which is a manufactured analog of the naturally occurring growth hormone-releasing hormone (GHRH). Ipamorelin belongs to the family of chemicals known as GHSR agonists, which contain synthetic pentapeptides. The ‘fragment’ 176–191 of growth hormone (hGH) is hypothesized as the “fat-burning peptide” because of its potential fat-burning impact within laboratory studies. Peptide AOD 9604 is constructed from the first 15 amino acids (177 to 191) of the growth hormone (hGH).
Fragment 176-191, Mod GRF 1-29 and Ipamorelin Peptide Blend and Lipolytic Action
In one research study, the impact of the peptide was investigated on obese laboratory animals over two weeks. After the study, it was hypothesized that the body weights of the mice had drastically dropped, along with the total fat in their bodies. These results were proposed to be connected to an increase in lipolytic ß3-AR receptors, which suggests that the peptides may function via the beta-adrenergic system. In the ensuing investigations, knockout mice lacking lipolytic receptors were used. The peptide seems to function independently of the lipolytic receptors since it may cause considerable weight loss in mice when given. The oxidation of fat and an increase in the amount of energy that is expended might be the methods by which this impact is produced. Studies suggest that while both hGH and AOD9604 may raise beta(3)-AR expression, which may eventually lead to higher lipolytic sensitivity, M Heffernan and colleagues speculated that “the lipolytic actions of both compounds are not mediated directly through the beta(3)-AR.” The studies suggest that increased beta(3)-AR expression may increase lipolytic sensitivity.
Fragment 176-191, Mod GRF 1-29, and Ipamorelin Peptide Blend and Appetite
Peptides were given to research models under observation; researchers examined what physiological reactions occurred throughout the experiment. As a consequence of this research, it was projected that these peptides might produce numerous changes in the bodies of its test subjects, including enhanced growth, hunger hormone signalling, lean body mass, deeper sleep cycles, and lower bone turnover in obese animals. These are all examples of changes that these peptides might cause. It has been purported that these peptides may affect “increasing lean body mass, reducing fat mass, increasing exercise tolerance and maximum oxygen uptake, enhancing muscle strength, and improving linear growth…”
Fragment 176-191, Mod GRF 1-29, and Ipamorelin Peptide Blend and Regeneration
One experiment conducted in 2018 included thirty-two rabbits, each divided into four groups of eight. A placebo, the Fragment 176-191 peptide, hyaluronic acid, and a combination of the peptide and hyaluronic acid were given to the study’s four groups of research models. This experiment lasted for around 6 and a half weeks in total. After the trial, every rabbit’s cartilage in the study was examined for signs of damage. The findings implied that compared to the other groups, the rabbits given the peptide and hyaluronic acid combination had the fewest visible symptoms of cartilage degeneration. The research findings purported that “AOD 9604 using ultrasound guidance enhanced cartilage regeneration, and combined AOD 9604 and HA was more effective than HA or AOD 9604 alone in the collagenase-induced knee OA rabbit model.”
Fragment 176-191, Mod GRF 1-29 and Ipamorelin Peptide Blend and Sleep
As suggested by several studies, daily growth hormone production may affect NREMS (deep non-REM sleep). Researchers hypothesize that a mixture of peptides that include Fragment 176-191, Ipamorelin, and Modified GRF 1-29 may be responsible for the enhanced growth hormone production and the changed sleep patterns that may occur. “Mutant and transgenic animals with a defect in GHRHergic activity display permanently reduced NREMS, which cannot be reversed using GH supplementation,” the research authors speculated. The quantity of GHRH produced in the hypothalamus and its mRNA level is connected with sleep-wake behavior during the day cycle and sleep restriction and restoration. The scientific community postulates that GHRH may stimulate NREMS by acting on the hypothalamus. GABAergic neurons in the anterior hypothalamus/preoptic area are potential candidates for mediating the activation of NREMS caused by GHRH.
Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend is only permitted at educational and research establishments; the study into these peptides is currently in progress and has not produced any definitive results. Licensed professionals may find the website www.corepeptides.com to be a useful resource. The website offers peptides that are of high quality, have a solid reputation, and are consistent. The substances mentioned in this paper have not been approved for human consumption.
References
[i] National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC.
[ii] Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo.142.12.8522. PMID: 11713213. https://pubmed.ncbi.nlm.nih.gov/11713213/
[iii] National Center for Biotechnology Information (2023). PubChem Substance Record for SID 319360420, 386264-39-7, Source: ToxPlanet. https://pubchem.ncbi.nlm.nih.gov/substance/319360420
[iv] Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/
[v] Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015 Summer;45(4):426-32. PMID: 26275694. https://pubmed.ncbi.nlm.nih.gov/26275694/
